(News Bulletin 247) – Invest Securities confirms its buy rating on the Valbiotis share with a price target raised from 10.3 to 12.3 euros

Yesterday evening, the laboratory announced the “large success” of a Phase II/III clinical study relating to a treatment against diabetes. This 3-year ‘clinical adventure’ achieved the objective on the main endpoint, i.e. the reduction in fasting blood sugar, ‘with strong statistical significance’, underlines Invest.

Despite the lack of comprehensive data (the full report on the data set is expected in the summer), the success of the study is very positive and will trigger a milestone payment of 4 million Swiss francs from Nestlé Health Science (NHS) under the Global Strategic Partnership.

‘This clinical success significantly reinforces the credibility of the group and validates the strategy’, emphasizes Invest Securities.

Copyright (c) 2023 News Bulletin 247. All rights reserved.